Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Optive Fusion vs Refresh Tears in Dry Eye Disease
NCT01294384Phase 3Completed
- Sponsor
- Allergan
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Polymer-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 3 trial of carboxymethylcellulose sodium ophthalmic gel, hyaluronic acid sodium salt in dry eye syndrome (DED), sponsored by Allergan. Started May 2011; status: completed.
02
Drugs
carboxymethylcellulose sodium ophthalmic gelhyaluronic acid sodium salt
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01294384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294384.